Search Results for "Torisel And Doxil And Avastin Bevacizumab"
Original Source: Doxil, Bevacizumab and Temsirolimus Trial
The goal of this clinical research study is to learn the highest safe doses of the combination of Doxil (liposomal doxorubicin), Avastin (bevacizumab), and Torisel (Temsirolimus) that can be given to patients with advanced cancer that has spread or is unable to be surgically removed. The safety and effectiveness of this combination of drugs will also be studied.
Matching Channels
Top 50 Biopharma Products 2011
Ronald A. Rader, president of the Biotechnology Information Institute provided Contract Pharma a list of the Top 57 Biopharma Products by 2011 revenues (in millions). Mr. Rader subscribes to the sam...
Matching News
Pfizer says Torisel combo fails in Ph III for kidney cancer
In a second research disappointment within a matter of days, US drugs behemoth Pfizer (NYSE: PFE) revealed on Friday that the Phase III INTORACT trial (B1771006) evaluating its Torisel (temsirolimus)...
Pfizer says Torisel-Avastin failed in cancer study
Pfizer said Friday that its drug Torisel failed to help patients with a form of advanced kidney cancer when combined with Roche's drug Avastin.The study compared renal cell carcinoma patients taking...
Pfizer's Torisel plus Avastin misses in first-line RCC
Pfizer Inc. (NYSE:PFE) said first-line treatment with IV Torisel temsirolimus plus Avastin bevacizumab missed the primary endpoint of improving progression-free survival (PFS) vs. Avastin plus interfe...
Pfizer's Torisel fails to hit targets in Avastin combo trial
Pfizer's Torisel fails to hit targets in Avastin combo trial
Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC
Pfizer Inc. announced today that the Phase 3 INTORACT trial (B1771006), evaluating the combination of bevacizumab plus TORISEL (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-α-...
Torisel-Avastin combo fails in kidney cancer
Combining Pfizer’s Torisel and Roche’s Avastin does not increase survival rates for advanced kidney cancer patients. This is according to a new Phase III trial investigating the two drugs as a fir...
EU agency backs Avastin (bevacizumab) for ovarian cancer
ZURICH (Reuters) - Swiss drugmaker Roche said on Friday European regulators had adopted a positive opinion of its drug bevacizumab (Avastin) for the treatment of women with advanced ovarian cancer...
ASCO: continued Avastin after progression increases overall survival in colon cancer
In metastatic colorectal cancer patients who had a follow-up round of second-line Roche/Genentech’s Avastin (bevacizumab) after their disease worsened following initial Avastin plus first-line c...
Matching PubMed Articles
Effects of Bevacizumab (Avastin®) on the Electroretinogram of Isolated Rat Retina.
Aim: To evaluate the in vitro effects of bevacizumab (Avastin®) on the electroretinogram (ERG) in rats using a model of isolated perfused retina ERG recording. Methods: Retinas were isolated from rat...
Changing End Points in Breast-Cancer Drug Approval - The Avastin Story.
In December 2007, the Oncologic Drugs Advisory Committee (ODAC) of the Food and Drug Administration (FDA) met to discuss the risks and benefits of Genentech's Avastin (bevacizumab) for use in combinat...
Bevacizumab (Avastin) in central retinal vein occlusion.
PURPOSE: Evaluate the use of bevacizumab (avastin) injected around valve body intraoperatively versus the use of mitomycin C as a single intraoperative application at the site of Ahmed valve implantat...
PURPOSE: To investigate the mechanism behind the aggregation breaking properties of dexamethasone phosphate and related corticosteroids on the IgG1 antibody bevacizumab (Avastin®). METHODS: An in sil...
